SITC Advances in Cancer Immunotherapy (ACI) for Radiation Oncologists

There is considerable research in preclinical and clinical domains that has investigated therapeutic interactions between radiation therapy and immunotherapies and these treatment modalities are increasingly being used in conjunction with each other. There is a critical need for clinicians and researchers to stay up to date with these developments in order to safely and effectively provide patient care and advance translational research objectives.

Participants of this activity learn the rationale for combining radiation therapy with different types of immunotherapy, as well as the factors that need to be considered as they may affect the efficacy of the treatment, including the radiation dose and field, and sequencing of radiation with immunotherapy. Learners gain an understanding of the current status of knowledge of the mechanisms of action of combinations of immunotherapeutic agents and radiation that can inform treatment decisions. Examples of specific clinical situations and clinical cases are discussed.

Topic:

  1. Introductions
    Sandra Demaria, MD
  2. The State of Science
    Zachary Scott Morris, MD, PhD 
  3. The State of Clinical Practice
    Jonathan Schoenfeld, MD
  4. The State of Clinical Translation
    James Welsh, MD
  5. Advancing Translational Research
    Kristina Young, MD, PhD
  6. Clinical Case Discussions
    Encouse Golden, MD, PhD
  7. Closing Remarks and SITC Resources
    Sandra Demaria, MD

This activity is available from December 2, 2024, through 11:59 p.m. Eastern time on December 1, 2026. 

This activity was originally recorded at the 2024 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation dosimetrists and radiation biologists.   

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement an optimal radiation delivery for patients treated with immunotherapy. 
  • Discuss combination treatment options for patients that may benefit from radiation and immunotherapy. 
  • Identify disease sites and stages that require special consideration in how radiation is delivered in combination with immunotherapy. 
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.
Course opens: 
12/02/2024
Course expires: 
12/01/2026
Cost:
$229.00
Rating: 
0
  • Sandra Demaria, MD, is employed by NewYork-Presbyterian/Weill Cornell Medical Center. Dr. Demaria receives honoraria from Lytix Biopharma and Johnson & Johnson. Dr. Demaria receives compensation from Boehringer Ingelheim. 
  • Zachary Scott Morris, MD, PhD, is employed by University of Wisconsin Hospitals and Clinics. Dr. Morris receives compensation and owns stock options with Archeus Technologies and Seneca Therapeutics. Dr. Morris receives honoraria and travel expenses from Northstar Medical Radioisotopes. Dr. Morris owns various patents through the Wisconsin Alumni Research Foundation. 
  • Jonathan D. Schoenfeld, MD, is employed by Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School. Dr. Schoenfeld receives compensation from Merck KGaA, EMD Serono, Immunitas and Intragel. Dr. Schoenfeld receives grant/research funding from EMD Serono, Merck, Bristol Myers Squibb, and Regeneron. Dr. Schoenfeld owns stock in Immunitas.   
  • James W. Welsh, MD, is employed by the University of Texas MD Anderson Cancer Center. Dr. Welsh receives grant/research funding from Varian, Nanobiotix, Novocure, Sciclone, Pebble Life Science, Bristol Myers Squibb, Artidis, AstraZeneca, Bayer Healthcare, Gilead, Kiromic, Takeda and Alkermes. Dr. Welsh receives compensation from Novocure, Kezar Life Sciences, Reflexion and Hotspot. Dr. Welsh has financial relationships in the form of ownership equity with Checkmate Pharmaceuticals, Molecular Match, Oligo Immune and Reflexion. 
  • Kristina H. Young, MD, PhD, is employed by The Oregon Clinic. Dr. Young receives grant/research funding from BMS, IMV Inc., Corbus Therapeutics and Bicara. Dr. Young receives salary support from Corbus Therapeutics and Bicara. Dr. Young is a shareholder of Synthis Bio. Dr. Young is a patent holder of Kristina Young, and serves in uncompensated roles with The Oregon Clinic (medical director and managing partner) and Synthis Therapeutics (scientific advisor). 
  • Encouse B. Golden, MD, PhD, is employed by NewYork-Presbyterian/Weill Cornell Medical Center.        

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.

Price

Cost:
$229.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

Nonmember: $229
Member: $149
Member-in-training: $79
Student/Grad Student/PGY: $79
Postdoctoral Fellow: $79
 

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website until December 1, 2026, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.